Core Viewpoint - Viatris Inc. (VTRS) reported better-than-expected first-quarter adjusted earnings of 50 cents per share, surpassing the Zacks Consensus Estimate of 49 cents, although down from 67 cents per share in the same quarter last year [1][15] Financial Performance - Total revenues for the quarter were $3.25 billion, reflecting an 11% year-over-year decline, but still exceeding the Zacks Consensus Estimate of $3.23 billion [1][15] - Adjusted gross margin decreased to 55.9% from 58.8% year-over-year [10] Sales Breakdown - Sales from Developed Markets were $1.9 billion, down 3% on a divestiture-adjusted operational basis, missing the Zacks Consensus Estimate of $1.93 billion [4] - Emerging Markets generated $519.9 million in sales, down 5% on a divestiture-adjusted operational basis, but beating the Zacks Consensus Estimate of $464 million [5] - Sales from Japan, Australia, and New Zealand (JANZ) totaled $276.1 million, down 6% and missing the Zacks Consensus Estimate of $309 million [5] - Greater China sales increased by 4% to $555.5 million, surpassing the Zacks Consensus Estimate of $553 million [5] Product Category Performance - Revenues from Brands decreased by 8% to $2.1 billion, but increased by 3% on a divestiture-adjusted operational basis [6] - Lipitor sales were $388 million, relatively flat year-over-year, while Norvasc and Lyrica sales declined [6] - Generics revenue was $1.1 billion, down 16%, with an operational decline of 11% [7][9] Future Guidance - Viatris maintains its total revenue guidance for 2025 at $13.5-$14 billion and adjusted earnings per share guidance at $2.16-$2.30, updated from a previous range of $2.12-$2.26 [12] Research and Development Updates - Positive results were reported from phase III studies for Effexor and a novel formulation of meloxicam, with plans to submit a new drug application to the FDA by the end of 2025 [13][14]